Mezun Olduğu Tıp Fakültesi ve Yılı
İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, 1998
Uzmanlık Eğitimi Aldığı Yer ve Yılı
Harvard Medical School HMX Pro Genetic-Essentials, Genetic-Cancer Genomics and Precision Oncology, 2023
Medikal Onkoloji Uzmanlığı, Ankara Numune Eğitim ve Araştırma Hastanesi, 2011
İç Hastalıkları Uzmanlığı, Uludağ Üniversitesi, 2004
Mesleki Deneyim
King Hamad University Hospital, Bahrain Oncology Center, Medical Oncology Department, (Professor), 2019 - 2024
Visitor scholar, Moffitt Cancer Center, Thoracic Oncology, Cutaneous Cancer Department, Tampa, FL, US, 2018 - 2019
Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi, Medikal Onkoloji Bilim Dalı, (Doçent), 2014 - 2019
Cumhuriyet Üniversitesi, Medikal Onkoloji Bilim Dalı, (Yardımcı Doçent), 2011 - 2013
Bursa Devlet Hastanesi, (Uzman Doktor), 2005 - 2008
Tıbbi İlgi Alanları
Meme Kanseri
Akciğer Kanseri
Melanoma
Gastrointestinal Sistem Kanserleri
Precision Medicine (Kişiselleştirilmiş Tıp) Tümör Genetiği
Immuno-Onkoloji
Hedefli Tedaviler
Klinik Çalışmalar
1. Ozkan, K., Turkkan, E., Ender, K., Mutlu, D., Murat, A., Nalan, B., A Yıldız, Osman, M. (2005). 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients. Indian Journal of cancer, 42(2), 85.
2. Odabas, H., Ozdemir, N., Isik, M., Abali, H., Oksuzoglu, B., Kos, T., B. Civelek, A.N. Babacan, U. Dogan, Zengin, N. (2010). Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. Journal of BU ON: official journal of the Balkan Union of Oncology, 16(3), 460-463.
3. Cihan, S., Uncu, D., Babacan, N. A., Özdemir, N., Odabaş, H., Aksoy, S.,Oksuzoglu B, Zengin, N. (2011). Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma. Asian Pac J Cancer Prev, 12(4), 967-970.
4. Kesikli, S. A., Eren, M. F., Akgul Babacan, N., & Kilickap, S. (2012). Prognosis of colorectal cancer with peritoneal carcinomatosis: Is a new staging necessary? Journal of Clinical Oncology, 30(18), 2287-2288.
5. Babacan, N. A., Aksoy, S., Cetin, B., Ozdemir, N. Y., Benekli, M., Uyeturk, U., M. Ali Kaplan, T. Kos, H. Karaca, B. Oksuzoglu, N. Zengin, S. Buyukberber (2012). Multiple primary malignant neoplasms: Multi-center results from Turkey. J BUON, 17(4), 770-5.
6. Demirci, U., Ozdemir, N., Benekli, M., Babacan, N. A., Cetin, B., Baykara, M., U. Coskun, N. Zengin, Buyukberber, S. (2012). Lymphoproliferative disorders in multiple primary cancers. Asian Pacific Journal of Cancer Prevention, 13(1), 383-386.
7. Budakoğlu, B., Aksoy, S., Arslan, Ç., Üyetürk, Ü., Babacan, N. A., Özcan, M. F., Ozcan, R. Yıldız, B.B. Oven, N.Y. Ozdemir, O. Dizdar, Büyükberber, S. (2012). Frequency of HCV infection in renal cell carcinoma patients. Medical Oncology, 29(3), 1892-1895.
8. Seker, M. M., Sancaktar, E., Acibucu, D. O., Filiz, A. K., Deveci, K., Bahceci, A., Kaçan T, Babacan N, Yuce, S. (2013). Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients. Eur Rev Med Pharmacol Sci, 17(21), 2929-2932.
9. Babacan, N. A., Yucel, B., Kilickap, S., Seker, M. M., Kacan, T., Olcas, I. K., Eren A.A., Odabas, H. (2013). Lung cancer in women: a single institution experience with 50 patients. Asian Pacific journal of cancer prevention: APJCP, 15(1), 151-154.
10. Yucel, B., Babacan, N. A., Kacan, T., Eren, A. A., Eren, M. F., Bahar, S., Celasun, M. G., Seker M.M, Hasbek, Z. (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pacific Journal of Cancer Prevention, 14(11), 6687-6692.
11. Bilici, A., Inanc, M., Ulas, A., Akman, T., Seker, M., Babacan N. A., A. İnal, , Bal O., Koral L., Sevinç A., Tufan G., Elkıran E.T., Oven Ustaalioglu B.B., Yavuzsen T., Alkıs N., Ozkan M., Gumus M.. (2013). Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology. Asian Pacific Journal of Cancer Prevention, 14(11), 6493-6499.
12. Yetisyigit, T., Babacan, N., Urun, Y., Seber, E. S., Cihan, S., Arpaci, E., N. Yıldırım, S. Aksoy, B. Budakoglu, N. Zengin, B. Oksuzoglu, B. Cicek Yalcın, N. Alkis, (2014). Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors. Asian Pac J Cancer Prev, 15(2), 831-5.
13. Kacan, T., Babacan, N. A., Seker, M., Yucel, B., Bahceci, A., Eren, Eren A. A., Eren M.F., Kılıckap S. (2014). Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers. Asian Pac J Cancer Prev, 15(5), 2089-2094.
14. Kilickap, S., Kaya, Y., Yucel, B., Tuncer, E., Babacan, N. A., & Elagoz, S. (2014). Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev, 15(3), 1381-1385.
15. Kacan, T., Altun, A., Altun, G. G., Kacan, S. B., Sarac, B., Seker M. M., Bahceci A, Babacan, N. (2014). Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells. Asian Pac. J. Cancer Prev, 15(7), 3185-3189.
16. Seker, M. M., Yucel, B., Seker, A., Eren, A. A., Bahar, S., Celasun, G.,Kacan T, Eren M.F., Babacan N, Bahceci, A. (2014). Treatment and prognosis of breast cancer in elderly: Different from young patients?. European Geriatric Medicine, 5(4), 261-264.
17. Yucel, B., Akkaş, E. A., Okur, Y., Eren, A. A., Eren, M. F., Karapınar, H.,Akgul Babacan N, Kılıçkap, S. (2014). The impact of radiotherapy on quality of life for cancer patients: a longitudinal study. Supportive Care in Cancer, 22(9), 2479-2487.
18. Seker, M. M., Sancakdar, E., Seker, A., Bahceci, A., Kacan, T., Babacan, N., S Yuce (2014). Prognostic value of serum TIE-2 and vascular endothelial growth factor levels in gastric cancer patients. (2014): e15085-e15085.
19. Seker, M. M., Uslu, A. U., Ozer, H., Seker, A., Kacan, T., Babacan. N.,Aker H, Elagoz, S. (2014). Orbital metastasis of endocervical stromal sarcoma: a rare tumor and an uncommon metastasis. Przeglad menopauzalny= Menopause review, 13(6), 356.
20. Yücel, B., Bahar, S., Kaçan, T., Seker, M. M., & Celasun, M. G. Bahceci A., Akgul Babacan N (2014). Importance of metastasis site in survival of patients with breast cancer. Austin J Med Oncol, 1(2), 7.
21. Cihan, S., Atasoy, A., Yildirim, Y., Babacan N. A., Kos, T. F. (2014). Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?. Tumori, 101(2), e40-5.
22. Cihan, S., Odabas, H., Ozdemir, N. Y., Yazilitas, D., Babacan, N. A. (2015). Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer. World Journal of Oncology, 6(1), 276-282
23. Babacan, N. A., Kiliçkap, S., Sene, S., Kacan, T., Yucel, B., Eren, M. F., Cihan, S. (2015). A case of multifocal skin metastases from lung cancer presenting with vasculitic-type cutaneous nodule. Indian journal of dermatology, 60(2), 213
24. Seker, M. M., Deveci, K., Seker, A., Sancakdar, E., Yilmaz, A., Turesin, A. K.,Kacan T, Babacan, N. A. (2015). Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. Asian Pac J Cancer Prev, 16, 407-410.
25. Yilmaz, M., Donmez, G., Kacan, T., Sari, I., Babacan N. A., Sari, M., Kilickap, S. (2015). Significant association between polymorphisms of Wnt antagonist genes and lung cancer. Journal of Investigative Medicine, 63(8), 935-941.
26. Tanrıkulu Sımsek E., Besiroglu M., Aktas B., Koca S., Halil Suleyman, Alan O., Hasanov R., Akgul Babacan N., Ozturk MA, Kaya S., Ozdogan OC, Dane F., Yumuk PF (2015). Can we restart vemurafenib after severe hepatotoxicity? A case report. JJ Gastro Hepato, 2(4):025.
27. Turan, N., Benekli, M., Unal, O. U., Unek, İ. T., Tastekin, D., Dane, F.,Algın E., Ulger S., Eren T., Ozturk Topcu T., Turkmen E., Akgul Babacan N ... & Buyukberber S. (2015) Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chinese Journal of Cancer Research, 27(4), 408.
28. Salman, A., Tekin, B., Koca, S., Babacan, N. A., Yumuk, P. F., Ergun, T. (2016). Another adverse effect of vemurafenib: Gingival hyperplasia. The Journal of dermatology, 43(6), 706-707.
29. Babacan, N. A., Eğilmez, H. R., Yücel, B., Parlak, I., Şeker, M. M., Kaçan, T., Bahceci A., Cıhan S., Akıncı B., Eriten B., Kılıçkap, S. (2016). The prognostic value of UHRF-1 and p53 in gastric cancer. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 22(1), 25.
30. Babacan, N. A. (2016). Will we have a new ending for Irvin Yalom's novel? A medical oncologist view. Journal of Oncological Science, 2(1), 5-6.
31. Kacan, T., Yucel, B., Bahar, S., Celasun, G., Seker, M. M., Babacan, N., Bahceci A., Kacan S., Kilickap, S. (2016). The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism. International Journal of Hematology and Oncology, 26(4), 136-144.
32. Kacan, T., Nayir, E., Altun, A., Kilickap, S., Babacan, N. A., Ataseven, H., Kaya, T. (2016). Antitumor activity of sorafenib on colorectal cancer. Journal of Oncological Sciences, 2(2), 53-57.
33. Kaya S, Aktas B, Tanrikulu Simsek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F.(2017). Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer. J BUON. 2017 Sep-Oct;22(5):1191-1198.
34. Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgul Babacan N, Dane F, Yumuk P Fulden (2018). Chordoma: a case series andreview of the literature. Journal of Medical Case Reports, 12:239.
35. Bahceci A, Seker M M, Kacan T, Akgul Babacan N, Yucel B, Gedikli A. Sunitinib induced cytopenia in metastatic RCC (2018). Clin Med Rev Case Rep, 5:208.
36. Alan, O., Ercelep, O., Telli, T. A., Tuylu, T. B., Önes, T., Bozkurtlar, E., NA Babacan ... & Kaya, S. (2018). P3. 16-48 Is Preoperative SUV (Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?. Journal of Thoracic Oncology, 13(10), S1020.
37. Karadurmus N., Sendur M. A. N., Karaca B., Olmez O. F., Hacibekiroglu I., Coskun H. S., Degirmencioglu S., Kemal Y., Kilickap S., Sumbul A. T., Aydin B., Turna H., Kaplan M. A., Babacan N., Demirci U., Ata A., Erdem D., Ozet A., Abali H. (2018). Experience from Turkish centers participating in the early access program (EAP): preliminary real world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. Journal of Oncological Science, https://doi.org/10.1016/j.jons.2018.10.001
38. Imeryuz, N., Atug, O., Kani, H. T., Alahdab, Y. O., Demirtas, C. O., Ozkan Gulsoy, H., O Ercelep, AE Atıcı, R Ergelen, IE Seven, NA Babacan... & Yemisci, I. (2019). Treatment of Hermansky-Pudlak syndrome Associated granulomatous colitis with anti-TNF agents: case series and review of literature.
39. Babacan, Nalan A., and Tawee Tanvetyanon. Superimposed Clostridium Difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis (2019). Journal of Immunotherapy, 42(9), 350-353
40. Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., VK Sondak, JL Messina, NA Babacan... & De Armas, L. (2019). Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine, 48, 178-190.
41. Tuylu, T. B., Demircan, N. C., Arikan, R., Telli, T. A., Alan, O., Ercelep, O., F Dane, MA Ozturk, NA Babacan… - ... & Lacin, T. (2019). P2. 06-22 Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?. Journal of Thoracic Oncology, 14(10), S763.
42. Ercelep, O., Alan, O., Sahin, D., Telli, T. A., Salva, H., Tuylu, T. B., NA Babacan... & Alkis, H. (2019). Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Clinical and Translational Oncology, 21(4), 499-504. doi: 10.1007/s12094-018-1949-6.
43. Demircan, N. C., Dane, F., Ozturk, M. A., Babacan, N. A., Besiroglu, M., Kaya, S., ... & Alan, O. (2019). Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. Liver, 232, 64-4.
44. Ercelep, Ö., Telli, T. A., Özkan, A. L. A. N., Hasanov, R., Şimşek, E. T., Babacan, N. A., ... & Yumuk, P. F. (2020). Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment? Single-Center Experience. Turkısh Journal Of Oncology, 1(3).
45. Demircan, N. C., Alan, Ö., Başoğlu Tüylü, T., Akın Telli, T., Arıkan, R., Çiçek, F. C., R Ergelen, I Tinay, N Akgül Babacan ... & P F Yumuk. (2020). Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. Journal of Oncology Pharmacy Practice, 26(5), 1147-1155.
46. Alan, O., Kuzhan, O., Koca, S., Telli, T. A., Basoglu, T., Ercelep, O., ... & Babacan, N. A. (2020). How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. Journal of Oncology Pharmacy Practice, 26(4), 1011-1018.
47. Eroglu, Z., Eatrides, J., Naqvi, S. M. H., Kim, Y., Rich, J., Babacan, N. A., ... & Khushalani, N. I. (2020). Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell & Melanoma Research, 33(1), 86-95.
48. Alan, O., Telli, T. A., Aktas, B., Koca, S., Ökten, I. N., Hasanov, R., MU Ugurlu, H Kaya, NA Babacan... & Kaya, S. (2020). Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?. World Journal of Surgical Oncology, 18(1), 1-9.
49. Babacan, N. A., Pina, I. B., Signorelli, D., Prelaj, A., Garassino, M. C., & Tanvetyanon, T. (2020). Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clinical Lung Cancer, 21(5), e456-e463.
50. Demirelli, B., Babacan, N. A., Ercelep, Ö., Öztürk, M. A., Kaya, S., Tanrıkulu, E., ... & Koca, S. (2020). Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutrition and Cancer, 1-9.
51. Telli, T. A., Demircan, N. C., Alan, O., Tuylu, T. B., Arikan, R., Ercelep, O., R Ergelen, IE Seven, NA Babacan ... & Kaya, S. (2020). A rare case of primary rectal choriocarcinoma and review of the literature. Journal of Oncology Pharmacy Practice, 26(4), 989-994.
52. Ercelep, O., Alan, O., Telli, T. A., Tuylu, T. B., Arıkan, R., Demircan, N. C., ET Simsek, NA Babacan ... & Bozkurtlar, E. (2020). Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori Journal, 0300891620950475.
53. Alan, O., Telli, T. A., Tuylu, T. B., Arikan, R., Demircan, N. C., Ercelep, O., S Kaya, NA Babacan ... & Bayri, Y. (2020). Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. Journal of Oncology Pharmacy Practice, 1078155220920684.
54. Babacan, N. A., Pina, I. B., Signorelli, D., Prelaj, A., Garassino, M. C., & Tanvetyanon, T. (2020). Relationship between programmed death receptor-ligand 1 expression and response to checkpoint inhibitor immunotherapy in pulmonary sarcomatoid carcinoma: a pooled analysis. Clinical lung cancer, 21(5), e456-e463.
55. Robinson, L. A., Babacan, N. A., Tanvetyanon, T., Henderson-Jackson, E., Bui, M. M., & Druta, M. (2020). Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas. The Journal of Thoracic and Cardiovascular Surgery.
56. Babacan, N. A., & Eroglu, Z. (2020). Treatment options for advanced melanoma after anti-PD-1 therapy. Current Oncology Reports, 22(4), 1-8.
57. Babacan, N. A., Peguero, E., Forsyth, P., & Eroglu, Z. (2021). BRAF Inhibitor Therapy‐Related Encephalitis in a Patient with Metastatic Melanoma. The Oncologist, 26(10), e1887-e1889.
58. Alan, O., Telli, T. A., Tuylu, T. B., Arikan, R., Demircan, N. C., Ercelep, O., Kaya, S., Babacan, N.A., Atasoy, B.M., Bozkurt, S. Bayri, Y.& Yumuk, P. F. (2021). Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. Journal of Oncology Pharmacy Practice, 27(2), 329-339.
59. Ercelep, O., Alan, O., Telli, T. A., Tuylu, T. B., Arıkan, R., Demircan, N. C., Simsek, E.T., Babacan, N.A., Kaya, S., Dane, F., Bozkurtlar, E. & Yumuk, P. F. (2021). Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori Journal, 107(3), 231-237.
60. Yildiz, F., Demirci, U., Küçükarda, A., Büyüksimsek, M., Sakalar, T., Topcu, T. O., Aslan, F., Tufan, G., Aydin, O., Turna, H. Babacan, N.A., Paydas, S. (2021). Merkel cell carcinoma in Turkey: A multicentric study. Journal of cancer research and therapeutics, 17(6), 1525.
61. Alan, O., Telli, T. A., Tuylu, T. B., Arikan, R., Demircan, N. C., Ercelep, O., Kaya, S., Babacan, N.A., Atasoy, B.M., Bozkurt, S. and Bayri, Y., Yumuk, P. F. (2021). Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. Journal of Oncology Pharmacy Practice, 27(2), 329-339.
62. Bahar-Ozdemir, Yeliz, Sefik Kaya, Nalan Akgul Babacan, Tugce Al, Ece Albayrak, Nilufer Coskun, and Gulseren Akyuz. "Can assessment of disease burden and quality of life based on mobility level in patients with end-stage cancer provide an insight into unmet needs? An exploratory cross-sectional study." Physiotherapy Theory and Practice (2022): 1-11.
63. Eroglu Z, Broman KK, Thompson JF,...Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi, Jonathan Zager, Nikhil I Khushalani. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection Journal for ImmunoTherapy of Cancer 2022;10:e004417. doi: 10.1136/jitc-2021-004417
64. Akin Telli, T., Ozturk, M.A., Alan, O., Hasanov, R., Kostek, O., Arikan, R., Basoglu, T., Kaya, S., Ercelep, O., Akgul Babacan, N. and Dane, F., 2022. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy. Future Oncology, 18(22), pp.2425-2439.
Türk Tıbbi Onkoloji Derneği
European Society of Medical Oncology (ESMO)
Doç. Dr. Nalan Akgül Babacan Medicana Sağlık Grubu'na ait MEDICANA ZİNCİRLİKUYU hastanesinde çalışmaktadır.
Doç. Dr. Nalan Akgül Babacan hekimimizin Medikal Onkoloji alanında uzmanlığı bulunmaktadır.
